Has Neel Shah, MD received payments from drug or device companies?

Yes. Drug and device makers reported $464,349 in general payments to Neel Shah, MD across 1,196 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Neel Shah, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Neel Shah, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Neel Shah, MD

Hematology & Oncology · Dyer, INNPI 1356508915

Payments from drug & device makers

$464,349in general payments, 2019–2025

Across 1,196 payments — averaging $388.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$126K
Karyopharm Therapeutics Inc.$71K
Regeneron Healthcare Solutions, Inc.$71K
Sanofi$58K
Jazz Pharmaceuticals Inc.$24K
Sirtex Medical Inc$21K
plus $92K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	173	$126,483
Karyopharm Therapeutics Inc.	52	$71,200
Regeneron Healthcare Solutions, Inc.	75	$70,888
Sanofi	83	$58,165
Jazz Pharmaceuticals Inc.	33	$24,459
Sirtex Medical Inc	33	$20,673
Genentech USA, Inc.	50	$15,271
Daiichi Sankyo Inc.	21	$14,779
AstraZeneca(2 entities)	63	$10,743
AMAG Pharmaceuticals, Inc.	12	$10,685
Eisai Inc.	28	$8,278
AbbVie	29	$7,267
GSK	16	$3,048
Pfizer	64	$3,046
Bristol Myers Squibb	65	$2,900
Incyte Corporation	22	$2,494
Novartis	59	$2,316
Beigene USA, Inc.	4	$1,949
Puma Biotechnology, Inc.	6	$1,182
Johnson & Johnson(3 entities)	28	$752
Merck	35	$695
Amgen	32	$656
Astellas Pharma US Inc	28	$558
Dr.reddy's Laboratories,inc.	1	$500
Tempus AI, Inc	5	$478
Pharmacosmos Therapeutics Inc.	2	$397
Gilead(2 entities)	19	$379
Athenex Pharmaceutical Division, LLC	2	$350
Exelixis Inc.	14	$300
Seagen Inc.	13	$285
Rigel Pharmaceuticals, Inc.	12	$267
Pharmacyclics LLC, An Abbvie Company	11	$265
Array Biopharma Inc	10	$195
Lilly USA, LLC	11	$193
Galvanize Therapeutics, Inc	1	$185
Bayer	11	$178
Janssen Scientific Affairs, LLC	1	$147
Cvrx, Inc.	1	$138
Tesaro, Inc.	5	$138
Fennec Pharmaceuticals, Inc.	1	$124
Takeda Pharmaceuticals U.S.A., Inc.	4	$111
Boehringer Ingelheim	4	$99
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$92
EMD Serono, Inc.	4	$79
Clovis Oncology, Inc.	6	$68
Deciphera Pharmaceuticals Inc.	3	$58
Foundation Medicine, Inc.	2	$50
Advanced Accelerator Applications	3	$44
Tolmar, Inc.	2	$44
Ipsen Biopharmaceuticals, Inc	2	$42
Mirati Therapeutics, Inc.	2	$41
Blueprint Medicines Corporation	2	$41
AVEO Pharmaceuticals, Inc.	2	$40
Sobi, Inc	2	$40
Tersera Therapeutics LLC	2	$37
Acrotech Biopharma Inc.	2	$35
Medtronic	2	$33
Dova Pharmaceuticals	2	$33
Beone Medicines USA, Inc.	1	$30
Alnylam Pharmaceuticals Inc.	1	$29

How this compares

$464,349 in reported general payments places this provider in the 85th percentile of 224 hematology & oncology providers in Indiana.

See all hematology & oncology providers in Indiana →

Medicare billing

Part B allowed, 2024

$7,316,307

Medicare patients

925

Services billed

304,284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Dyer

Shruti SinghDyer$884K
Mohamad KassarDyer$205K
Gregory DurmIndianapolis$22.7M
Nabil AdraIndianapolis$13.2M
Attaya SuvannasankhaIndianapolis$8.2M
Zhentao ZhangFort Wayne$6.4M
Shadia JalalIndianapolis$4.6M
Ahad SadiqFort Wayne$4M
Ruemu BirhirayIndianapolis$4M
Richard GaynorIndianapolis$3.7M

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →